BiotechTube
Home/Pipeline/Trichostatin A (TSA)

Trichostatin A (TSA)

Hematologic Malignancies

Oncology ProgramIn Development

Key Facts

Indication
Hematologic Malignancies
Phase
Oncology Program
Status
In Development
Company
Vanda Pharmaceuticals

About Vanda Pharmaceuticals

Founded in 2003 and publicly traded on NASDAQ (VNDA), Vanda Pharmaceuticals leverages genetics and genomics to inform drug discovery and development. The company has achieved significant milestones with FDA approvals for Fanapt® (2009) and HETLIOZ® (2014), and continues to expand its pipeline with late-stage candidates like tradipitant and imsidolimab. Vanda's strategic focus combines commercial execution with a science-driven approach to address complex disorders in circadian rhythms, psychiatry, and inflammation.

View full company profile

Therapeutic Areas

PsychiatrySleep DisordersCircadian Rhythm DisordersDermatologyGastroenterologyOncologyImmunology

Other Hematologic Malignancies Drugs

DrugCompanyPhase
SHR-1905Jiangsu Hengrui MedicinePhase 1
Rituximab biosimilar (IBI301)Innovent BiologicsApproved
Alemtuzumab BiosimilarCSPC Pharmaceutical Group LimitedPhase 3
Lead CAR-T ProgramArcellxPhase 1
KT-333Kymera TherapeuticsPhase 1
Undisclosed CAR-T programsBeam TherapeuticsDiscovery/Preclinical
NX-1607Nurix TherapeuticsPhase 1a
Cord Blood HSC UnitGlobal Cord BloodApproved/Commercial
TSC-102-A01TScan TherapeuticsPreclinical
TSC-102-A03TScan TherapeuticsPreclinical
LBL-007LakeShore BiopharmaPhase 1
CER-T Cell PlatformCERo TherapeuticsPre-clinical